Malignancy Flashcards
what are the monitoring requirements of ciclosporin?
LFT
Mg
K
lipids
CrCl
BP
what are the side effects of ciclosporin?
hyperglycaemia, hyperlipidaemia, hyperuricemia, hyperkalaemia
hypo/hyper tension
renal/ liver impairment
skin reactions
gingival hyperplasia
visual changes
- avoid UV light
what is the monitoring requirements of tacrolimus?
BP
ECG
LFT
electrolytes
blood glucose
CrCl
what is the link between tacrolimus and macrolides?
do not use tacrolimus if hypersensitivity to macrolides
what are the side effects of tacrolimus?
hyperglycaemia, hyperuricaemia, hyperkalaemia
hypo/hyper tension
renal/ liver impairment
skin reactions
visual disturbances
blood dyscrasias
QT prolongation
cardiomyopathy in children
peripheral neuropathy
- avoid UV light
what are the side effects of mycophenolate?
pure red cell aplasia
bone marrow suppression
hypogammaglobulin
bronchiectasis
contraception:
women - during and 6 weeks after
men - during and 90 days after
which chemotherapy drug is associated with pulmonary fibrosis?
bleomycin
which chemotherapy drugs are associated with ototoxicity and nephrotoxicity?
cisplatin and carboplatin
which chemotherapy drug is associated with cardiotoxicity?
doxorubicin
which chemotherapy drugs are associated with myelosuppression and oral mucositis?
methotrexate and 5-flouracil
which chemotherapy drug is associated with neurotoxicity?
nitrosoureas (lomustine and carmustin)
which chemotherapy drug is associated with haemorrhagic cystitis?
cyclophosphamide
which chemotherapy drugs are associated with peripheral neuropathy?
taxanes and vinka alkaloids
which chemotherapy drugs have a high emetic potential?
cisplatin, dacarbazine, and high doses of cyclophosphamide
how do you manage emesis in chemotherapy?
For patients at low risk of emesis, pretreatment with dexamethasone or lorazepam may be used
For patients at high risk of emesis, a 5HT3-receptor antagonist, usually given by mouth in combination with dexamethasone and the neurokinin receptor antagonist aprepitant is effective
